ESSA Pharma Inc
NASDAQ:EPIX
Intrinsic Value
The intrinsic value of one
EPIX
stock under the Base Case scenario is
3.79
USD.
Compared to the current market price of 2.9 USD,
ESSA Pharma Inc
is
Undervalued by 24%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
EPIX Profitability Score
Profitability Due Diligence
ESSA Pharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
ESSA Pharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
EPIX Solvency Score
Solvency Due Diligence
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
ESSA Pharma Inc
| Current Assets | 165M |
| Cash & Short-Term Investments | 163M |
| Receivables | 14.6k |
| Other Current Assets | 1.5M |
| Non-Current Assets | 416k |
| PP&E | 156k |
| Other Non-Current Assets | 259k |
| Current Liabilities | 2.9M |
| Accounts Payable | 1.6M |
| Accrued Liabilities | 1.3M |
| Other Current Liabilities | -10 |
| Non-Current Liabilities | 48.3k |
| Other Non-Current Liabilities | 48.3k |
EPIX Capital Structure
ESSA Pharma Inc
| Market Capitalization | 128M USD | |
| Total Debt | 0 USD | |
| Minority Interest | 0 USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 51.2M USD | |
| Short-Term Investments | 112M USD | |
| Enterprise Value | -35.2M USD | |
Wall St
Price Targets
EPIX Price Targets Summary
ESSA Pharma Inc
Ownership
EPIX Insider Trading
Buy and sell transactions by insiders
During the last 12 months ESSA Pharma Inc insiders bought 11M USD , and sold 876k USD worth of shares. The last transaction was made on Mar 25, 2023 by Parkinson David Ross (Chief Executive Officer), who bought 8k USD worth of EPIX shares.
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
N/A
|
29.6k
USD
|
29.6k
|
| 6 Months |
729k
USD
|
8.3M
USD
|
7.6M
|
| 9 Months |
729k
USD
|
11M
USD
|
10.3M
|
| 12 Months |
876k
USD
|
11M
USD
|
10.1M
|
Shareholder Return
EPIX Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
EPIX Price
ESSA Pharma Inc
| Average Annual Return | 63.55% |
| Standard Deviation of Annual Returns | 94.13% |
| Max Drawdown | -96% |
| Market Capitalization | 128M USD |
| Shares Outstanding | 44 092 400 |
| Percentage of Shares Shorted | 1.62% |
Company Profile
ESSA Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
Contact
IPO
Employees
Officers
The intrinsic value of one
EPIX
stock under the Base Case scenario is
3.79
USD.
Compared to the current market price of 2.9 USD,
ESSA Pharma Inc
is
Undervalued by 24%.
